FY2024 Earnings Estimate for CRSP Issued By HC Wainwright

CRISPR Therapeutics AG (NASDAQ:CRSP) – Stock analysts at HC Wainwright issued their FY2024 earnings per share estimates for shares of CRISPR Therapeutics in a note issued to investors on Monday, February 3rd. HC Wainwright analyst M. Kapoor expects that the company will post earnings per share of ($4.83) for the year. HC Wainwright currently has a “Buy” rating and a $65.00 price target on the stock. The consensus estimate for CRISPR Therapeutics’ current full-year earnings is ($5.10) per share. HC Wainwright also issued estimates for CRISPR Therapeutics’ Q4 2024 earnings at ($0.98) EPS, Q1 2025 earnings at ($1.11) EPS, Q2 2025 earnings at ($1.01) EPS, Q3 2025 earnings at ($1.11) EPS, Q4 2025 earnings at ($1.03) EPS and FY2025 earnings at ($4.25) EPS.

Other equities research analysts have also issued research reports about the stock. Needham & Company LLC reaffirmed a “buy” rating and set a $84.00 target price on shares of CRISPR Therapeutics in a research note on Tuesday, January 14th. Bank of America cut their price objective on CRISPR Therapeutics from $98.00 to $85.00 and set a “buy” rating on the stock in a research report on Tuesday, January 7th. Chardan Capital reiterated a “buy” rating and issued a $94.00 price target on shares of CRISPR Therapeutics in a research note on Tuesday, December 10th. StockNews.com upgraded CRISPR Therapeutics to a “sell” rating in a research note on Monday, December 30th. Finally, JMP Securities reissued a “market outperform” rating and issued a $86.00 target price on shares of CRISPR Therapeutics in a report on Friday, December 20th. Two research analysts have rated the stock with a sell rating, eight have issued a hold rating and eleven have assigned a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and an average price target of $77.59.

CRISPR Therapeutics Stock Up 4.3 %

Shares of CRISPR Therapeutics stock opened at $42.22 on Wednesday. The company has a market cap of $3.60 billion, a PE ratio of -14.92 and a beta of 1.67. The business has a 50 day moving average of $43.20 and a 200 day moving average of $46.82. CRISPR Therapeutics has a 52 week low of $36.52 and a 52 week high of $91.10.

CRISPR Therapeutics (NASDAQ:CRSP) last posted its earnings results on Tuesday, November 5th. The company reported ($1.01) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.42) by $0.41. CRISPR Therapeutics had a negative return on equity of 12.15% and a negative net margin of 118.13%. The company had revenue of $0.60 million for the quarter, compared to analysts’ expectations of $6.65 million. During the same period last year, the firm earned ($1.41) earnings per share.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. Highline Wealth Partners LLC purchased a new stake in shares of CRISPR Therapeutics in the 4th quarter worth $39,000. Western Pacific Wealth Management LP grew its position in shares of CRISPR Therapeutics by 100.0% during the 4th quarter. Western Pacific Wealth Management LP now owns 1,000 shares of the company’s stock valued at $39,000 after acquiring an additional 500 shares during the period. Wilmington Savings Fund Society FSB acquired a new position in shares of CRISPR Therapeutics during the 3rd quarter worth approximately $40,000. Darwin Wealth Management LLC acquired a new stake in shares of CRISPR Therapeutics in the third quarter valued at about $43,000. Finally, Eastern Bank purchased a new stake in shares of CRISPR Therapeutics during the third quarter worth approximately $70,000. 69.20% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 15,000 shares of the company’s stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $55.10, for a total value of $826,500.00. Following the completion of the transaction, the chief executive officer now directly owns 181,540 shares in the company, valued at $10,002,854. This represents a 7.63 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 4.10% of the stock is owned by company insiders.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.